Almac Group has reported an £85.4 million rise in turnover from £548.9 million to £634.3 million for its financial year 2018-19.
During this period, the revenue increase resulted in improved pre-tax profits which were recorded at £47.6 million, up from £27.6 million for the same period the previous year. Higher exchange gains on financial activities in the year also contributed to this profit level improvement.
Average employee figures increased from 4,798 to 5,150 during the same period. These figures were recorded in the organization’s annual report for year ending 30 September 2019.
Throughout this period, the Group continued to invest in its existing facilities across UK, Europe, North America and Asia. In addition, the organization launched a number of innovative and unique solutions designed to offer greater efficiency to its global clients within the diagnostic, clinical trial and pharmaceutical development arenas.
“These results show a strong growth trajectory which is testament that our strategy of investing significantly in our people, facilities and unique solutions is clearly effective. With 100% of our profits reinvested into our business, we will continue to innovate and improve our wide range of services and products to ensure we provide the premium solutions our global client base relies on,” Alan Armstrong, Group CEO, said. “These results are for our 2018-19 financial year and, since then, much has changed in our industry. In response to the COVID-19 pandemic, we continue to conduct our critical business operations across all our locations. The health and safety of our employees and our ability to ensure the delivery of medicines to patients is, and always has been, our top priority and we are committed to ensure this continues."